A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: Structural outcomes

Clinical and Experimental Rheumatology

Volumn 27, Issue 4 SUPPL. 55, 2009, Pages

  Landewé, Robert ^a   Van Der Heijde, Désirée ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ankylosing spondylitis; Conventional radiography; Imaging; Psoriatic arthritis; Scoring methods; Spondyloarthritis; Structural damage

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; BONE DISEASE; BONE EROSION; BONE RADIOGRAPHY; CARTILAGE INJURY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; JOINT FUNCTION; JOINT INJURY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNDESMOPHYTE; TISSUE STRUCTURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; HUMANS; JOINTS; SPINE; SPONDYLITIS, ANKYLOSING;

EID: 71249140251     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. ALETAHA D, SMOLEN J, WARD MM: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-2792
2. LANDEWÉ RB, GEUSENS P, VAN DER HEIJDE DM, BOERS M, VAN DER LINDEN SJ, GARNERO P: Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis 2006; 65: 40-44
3. LARSEN A, DALE K: Standardized radiological evaluation of rheumatoid arthritis in therapeutic trials. In DUMONDE DC, JASANI JK (Eds.) Recognition of Anti-Rheumatic Drugs 1977: 285-292. Lancaster: MTP Press.
4. SHARP JT, LIDSKY MD, COLLINS LC, MORELAND J: Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706-720
5. VAN DER HEIJDE D: How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26: 743-745
6. ROMAS E, BAKHAREVSKI O, HARDS DK et al.: Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000; 43: 821-826
7. GRAVALLESE EM, MANNING C, TSAY A et al.: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 250-258
8. HAYNES D, CROTTI T, WEEDON H et al.: Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum 2008; 59: 911-920
9. RITCHLIN CT, HAAS-SMITH SA, LI P, HICKS DG, SCHWARZ EM: Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-831
10. TERPOS E, SZYDLO R, APPERLEY JF et al.: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-1069
11. GEUSENS PP, LANDEWÉ RB, GARNERO P et al.: The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772-1777
12. COHEN SB, DORE RK, LANE NE et al.: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-1309
13. DROSSAERS-BAKKER KW, DE BUCK M, VAN ZEBEN D, ZWINDERMAN AH, BREEDVELD FC, HAZES JM: Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854-1860
14. SCOTT DL, SMITH C, KINGSLEY G: Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S20-7.
15. WELSING PM, VAN GESTEL AM, SWINKELS HL et al.: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009-2017
16. WELSING PM, LANDEWÉ RB, VAN RIEL PL et al.: The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50: 2082-2093
17. LUKAS C, LANDEWÉ RB, FATENEJAD S, VAN DER HEIJDE DM: Subtle changes in individual joints result in both positive and negative change scores in a patient: Results from a clinical trial in patients with rheumatoid arthritis. Ann Rheum Dis 2008.
18. VAN DER HEIJDE D, LANDEWÉ R, BOONEN A et al.: Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. Arthritis Res Ther 2007; 9: R62.
19. VAN DER HEIJDE D, LANDEWÉ R, VAN VOLLENHOVEN R, FATENEJAD S, KLARESKOG L: Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008; 67: 1267-1270
20. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368
21. MACKAY K, MACK C, BROPHY S, CALIN A: The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998; 41: 2263-2270
22. DAWES P, AVERNS H, TAYLOR HG, DZIEDZIC KD, JONES PW: Stoke Ankylosing Spondylitis Spinal Score (SASSS). J Rheumatol 1999; 26: 993-996
23. CREEMERS MC, FRANSSEN MJ, VAN'T HOF MA, GRIBNAU FW, VAN DE PUTTE LB, VAN RIEL PL: Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 127-129
24. WANDERS AJ, LANDEWÉ RB, SPOORENBERG A et al.: What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004; 50: 2622-2632
25. WANDERS A, LANDEWÉ R, DOUGADOS M, MIELANTS H, VAN DER LINDEN S, VAN DER HEIJDE D: Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005; 64: 988-994
26. VAN DER HEIJDE D, BARAF HS, RAMOS-REMUS C et al.: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-1215
27. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193
28. VAN DER HEIJDE D, LANDEWÉ R, VAN DER LINDEN S: How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005; 52: 1979-1985
29. MAKSYMOWYCH WP, LANDEWÉ R, CONNER-SPADY B et al.: Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56: 1846-1853
30. WANDERS A, HEIJDE DV, LANDEWÉ R et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005; 52: 1756-1765
31. BRAUN J, LANDEWÉ R, HERMANN KG et al.: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54: 1646-1652
32. VAN DER HEIJDE D, LANDEWÉ R, BARALIAKOS X et al.: Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: 3063-3070
33. VAN DER HEIJDE D, LANDEWÉ R, EINSTEIN S et al.: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324-1331
34. DIARRA D, STOLINA M, POLZER K et al.: Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156-163
35. MILLER JR: The Wnts. Genome Biol 2002; 3: REVIEWS 3001.
36. GLASS DA, 2ND, BIALEK P, AHN JD et al.: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751-764
37. BRUYNESTEYN K, LANDEWÉ R, VAN DER LINDEN S, VAN DER HEIJDE D: Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. Ann Rheum Dis 2004; 63: 1413-1418